PTI-104 / Postsurgical Therap - LARVOL DELTA

Overcoming Resistance and Toxicity Hurdles: PST's Localized Drug Delivery Technology May Unlock Combined MEK/mTOR Inhibition For Multiple KRAS+ Tumors Types (PRNewswire) - "Postsurgical Therapeutics, Inc...announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types of KRAS mutated solid tumors. The results demonstrated suppression or elimination of tumors in mice. The drugs were developed and commercialized by others for oral administration...PST's proprietary controlled release gel formulation of the drugs was administered by intratumoral injection to the target tumors. The drugs used target the MAPK and PI3K pathways using a combination of MEK and mTOR inhibitors, which are important for treatment of several major tumor types. The formulation was shown to be effective, reducing growth or eradicating tumors in several KRAS mutations across multiple cancer cell lines, including pancreatic (Mia PaCa-2, G12C), lung (NCI H441, G12V), colorectal (SW3, G12V), and gastric (AGS, G12D) cancers."

Preclinical • Colorectal Cancer • Gastric Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor